Valuation: Voyager Therapeutics, Inc.

Market Cap 177M 156M 147M 134M 250M 16.98B 252M 1.76B 682M 8.64B 664M 650M 28.11B P/E 2026 *
-1.7x
P/E 2027 * -2.28x
Enterprise Value 58.54M 51.49M 48.54M 44.29M 82.83M 5.62B 83.47M 583M 226M 2.86B 220M 215M 9.31B EV / Sales 2026 *
2.89x
EV / Sales 2027 * 0.87x
Free-Float
85.16%
Yield 2026 *
-
Yield 2027 * -
1 day-6.15%
1 week-6.42%
Current month-18.71%
1 month-11.61%
3 months-21.95%
6 months-23.93%
Current year-26.78%
1 week 2.39
Extreme 2.39
2.62
1 month 2.39
Extreme 2.39
2.94
Current year 2.39
Extreme 2.39
4.38
1 year 2.39
Extreme 2.39
4.87
3 years 2.22
Extreme 2.218
10.1
5 years 2.1
Extreme 2.098
13.2
10 years 2.1
Extreme 2.098
25.12
Manager TitleAgeSince
Chief Executive Officer 68 22/03/2022
Chief Tech/Sci/R&D Officer 56 01/11/2018
Director of Finance/CFO 55 01/04/2024
Director TitleAgeSince
Director/Board Member 71 01/01/2014
Director/Board Member 73 17/09/2015
Director/Board Member 70 05/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-8.71%-6.42% - - 177M
+1.46%+5.87%+5.75%+33.71% 47.56B
+2.67%+2.07%+51.74%+35.89% 44.09B
-1.38%+1.84%+9.13%+89.08% 41.5B
+4.78%+1.48%+359.03%+577.49% 40.88B
-0.62%+0.11%+1.12%+46.02% 29.67B
+0.56%+0.88%+24.79%+153.61% 17.23B
+2.05%+4.04%+24.47%+41.67% 15.06B
+3.39%-3.49% - - 14.65B
+7.38%+2.34%+3.80% - 13.82B
Average +1.41%+0.69%+59.98%+139.64% 29.39B
Weighted average by Cap. +1.88%+0.96%+74.03%+148.86%

Financials

2026 *2027 *
Net sales 20.28M 17.83M 16.81M 15.34M 28.69M 1.95B 28.91M 202M 78.18M 991M 76.13M 74.47M 3.22B 46.58M 40.97M 38.63M 35.24M 65.91M 4.47B 66.42M 464M 180M 2.28B 175M 171M 7.41B
Net income -106M -93.37M -88.02M -80.31M -150M -10.19B -151M -1.06B -409M -5.19B -399M -390M -16.88B -88.66M -77.99M -73.52M -67.08M -125M -8.51B -126M -882M -342M -4.33B -333M -326M -14.1B
Net Debt -118M -104M -98.09M -89.5M -167M -11.36B -169M -1.18B -456M -5.78B -444M -435M -18.81B -136M -120M -113M -103M -193M -13.1B -195M -1.36B -526M -6.67B -513M -501M -21.7B
Logo Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
Employees
141
Date Price Change
24/09/26 €2.390 -8.71%
23/09/26 €2.618 +2.35%
22/09/26 €2.558 -0.78%
21/09/26 €2.578 +1.90%
18/09/26 €2.530 -0.71%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.870USD
Average target price
14.89USD
Spread / Average Target
+418.78%

Quarterly revenue - Rate of surprise